InspireMD director awarded 88,053 restricted shares
InspireMD, Inc. director Scott R. Ward reported an equity award of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InspireMD, Inc. director Scott R. Ward reported an equity award of common stock. On January 14, 2026, he received 88,053 shares of common stock at a price of $0 per share, characterized as an acquisition. These shares are restricted stock that will vest on January 14, 2027, as long as he continues in service with the company through that date. Following this grant, he beneficially owns 147,846 shares of InspireMD common stock directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 88,053 | $0.00 | $0.00 |
Footnotes (1)
- F1. These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did InspireMD (NSPR) disclose in this Form 4?
The filing shows that director Scott R. Ward acquired 88,053 shares of InspireMD common stock on January 14, 2026 in a reported acquisition transaction.
What is Scott R. Ward’s role at InspireMD (NSPR)?
The filing identifies Scott R. Ward as a director of InspireMD, Inc. He is not listed as an officer or a 10% beneficial owner in this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.